New immunotherapy 麻薬 shows 約束 as 癌 治療, 研究 示唆するs
A new class of immunotherapy could 申し込む／申し出 hope to 癌 患者s who do not 答える／応じる to 存在するing 治療s, 研究 示唆するs.
The 熟考する／考慮する 設立する the 麻薬, called MOv18 IgE, shrank a tumour in a 患者 with ovarian 癌 and 報告（する）／憶測d that it was 井戸／弁護士席 許容するd in 患者s.
The scientists 示唆する their findings could 可能にする a 完全に new type of anti-癌 麻薬 for people with chemotherapy-抵抗力のある 癌s.
The 熟考する／考慮する by 研究員s from King’s College London and Guy’s and St Thomas’ NHS 創立／基礎 信用, and 基金d by 癌 研究 UK, 実験（する）d whether a type of antibody called IgE could be used to 扱う／治療する human 癌.
Immunotherapy 作品 by 刺激するing the 団体／死体’s natural defence system to attack 癌.
存在するing antibody 麻薬s used in 癌 belong to an antibody type called IgG, but IgE antibodies have not been 実験（する）d in humans before.
臨床の 裁判，公判 shows 約束 for new antibody 癌 治療 (Jeff Moore/PA)
IgE antibodies 発展させるd to 的 parasites like worms and flukes, and IgG antibodies are 伴う／関わるd in attacking bacteria and ウイルスs in the 団体／死体.
Lead author on the 熟考する／考慮する, Professor James Spicer, professor of 実験の 癌 薬／医学 at King’s College London and 顧問 in 医療の Oncology at Guy’s and St Thomas’ NHS 創立／基礎 信用 (GSTT), said: “IgE is a 完全に new form of antibody therapy which has shown 広大な／多数の／重要な 約束 in this 段階 I 裁判，公判.
“Our findings show that the 麻薬 was 井戸／弁護士席 許容するd in 患者s and shrunk a cancerous tumour in a 患者 with ovarian 癌.
“The results 覆う the way to 開発 of an 完全に new class of anti-癌 麻薬 for people with chemotherapy-抵抗力のある 癌s.
“The immunology 専門的知識 in King’s College London 研究室／実験室s 許すd us to 請け負う this 裁判，公判 of a 完全に new form of antibody therapy.”
Co-author Sophia Karagiannis, professor of translational 癌 immunology and immunotherapy at King’s College London, said: “Immunotherapy has shown enormous 可能性のある recently but there are still people with 癌 who do not 答える／応じる to 従来の therapy.
“This 裁判，公判 builds on our previous work into the biology of IgE, 含むing 実験s in the 研究室／実験室 示唆するing that IgE could be an 効果的な 治療 that can 申し込む／申し出 付加 利益s to complement those of 設立するd IgG antibodies in the clinic.
“While we are still in the 早期に 行う／開催する／段階 of 裁判，公判s, our next steps will be to 評価する IgE in larger and different groups of 患者s and to continue 熟考する／考慮するing how IgE antibodies are able to wake up the 患者’s 免疫の system to fight different 癌s.”
The MOv18 IgE antibody was discovered and developed at King’s College London, in 共同 with IRCCS Instituto Nazionale dei Tumori, Milan, Italy, and clinically 実験（する）d by the 実験の 癌 薬／医学 Centre based at Guy’s Hospital.
The 熟考する／考慮する, 基金d and sponsored by 癌 研究 UK, is published in Nature Communications.
